Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

Autor: Yi‐Long Wu, Shun Lu, Ying Cheng, Qing Zhou, Hai‐Yan Tu, Qing‐Hua Zhou, Lv‐Hua Wang, Li Zhang, Jian‐Ying Zhou, Cheng Huang, Ming Chen, Cheng‐Ping Hu, Shao‐Kun Chuai, Xiao‐Nan Wang, Xiao‐Qing Liu, Ji‐Wei Liu, Peng‐Hui Zhou, Wei‐Zhi Chen, Ling‐Hua Yan, Yun‐Peng Liu, An‐Wen Liu, Xu‐Chao Zhang, Hui Li, Rong‐Rong Chen, Dong‐Mei Lin, Cong‐Ying Xie, Zheng‐Fei Zhu, Hui‐Ying Liang, Yong Song, Xiao‐Rong Dong, Ming‐Fang Zhao, Gui‐Bin Qiao, Jiu‐Wei Cui, Zi‐Ming Li, Zhi‐Jie Wang, Xiao‐Yuan Chen, Nong Yang, Gen Lin, Pan‐Wen Tian, Yun Fan, Qi‐Bin Song, Yuan Chen, Jian‐Chun Duan, Jia‐Lei Wang, Bo Zhu, Bu‐Hai Wang, Jun Zhao, Qi‐Tao Yu, Li‐Feng Wang, Hai‐Bo Zhang, Jie Hu, Rui Ma, Tong‐Mei Zhang, Jie Lin, Qian Chu, Sheng‐Xiang Ren, Yu Yao, Lin Wu, Hui‐Juan Wang, Fang Wu, Wen‐Zhao Zhong, Yi Hu, Ke‐Neng Chen, Jian Zhao, Fan Yang, Qun Wang, Dong‐Sheng Yue, Jian‐Ya Zhou, Peng Shen, Jia‐Tao Zhang, Xiao‐Long Yan, Mei‐Juan Huang, Wei‐Neng Feng, Li Li, Chinese Association of Lung Cancer, Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG)

Publikováno v: Medicine Advances, Vol 1, Iss 4, Pp 293-305 (2023)

Abstract The importance of uncommon/rare oncogenic drivers in non‐small cell lung cancer (NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers, while present in a significant proportion of NSCLC patients, remain a challeng

Externí odkaz: https://doaj.org/article/6cf86ef452334af4a74e37fd66750545

Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non–Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)

Autor: Si-Yang Maggie Liu, Hong-Hong Yan, Xue-Wu Wei, Chang Lu, Xiao-Rong Dong, Yingying Du, Jiu-Wei Cui, Yuan Chen, Rui Ma, Bu-Hai Wang, Zhen Zhou, Shun-Dong Cang, Jin-Ji Yang, Hai-Yan Tu, Xu-Chao Zhang, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu

Publikováno v: Clinical Lung Cancer. 23:e395-e399

With rare genetic variations having been increasingly recognized at a preclinical stage, a variety of early-phase clinical trials have been launched. Due to the low incidence rate of these variations, although the sample size of trials are small, it

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac4c937cc5a9f821e6e6d87e2faf61bc
https://doi.org/10.1016/j.cllc.2022.05.009

Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study

Autor: Lunxu Liu, Chun Chen, Ke-Neng Chen, Lin Xu, Xue-Ning Yang, Lin Wu, Cheng Huang, Hong-Hong Yan, Shidong Xu, Weimin Mao, Yi-Long Wu, Ke Fei, Yongyu Liu, Songtao Xu, Bu-Hai Wang, Ying Cheng, Xiaofei Li, Qun Wang, Zhidong Liu, Yi Shen, Jian Li, Qing Zhou, Wen-Zhao Zhong, Haitao Ma, Ping Yu, Qixun Chen, Jun Wang, Jian Zeng, Taobo Luo, Shun Xu

Publikováno v: Lung Cancer. 150:164-171

Objectives Health-related quality of life (HRQoL) data complement conventional clinical endpoints when comparing adjuvant gefitinib with chemotherapy in patients with early-stage non-small-cell lung cancer (NSCLC) and epidermal growth factor receptor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df5863b73dbc9f0c1a5a30c22f392ccd
https://doi.org/10.1016/j.lungcan.2020.09.027

The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

Autor: Ke-Neng Chen, Chun Chen, Shun Xu, Wen-Zhao Zhong, Lunxu Liu, Cheng Huang, Ying Cheng, Zhidong Liu, Xue-Ning Yang, Yongyu Liu, Yi-Long Wu, Hong-Hong Yan, Bu-Hai Wang, Junjie Xi, Xiaofei Li, Ping Yu, Jia-Cheng Yin, Yongxing Zhang, Lin Xu, Qun Wang, Shidong Xu, Yi Shen, Jian Li, Song-Tao Xu, Weimin Mao, Ke Fei, Jun Wang, Lin Wu, H. Ma

Publikováno v: Journal of Thoracic Oncology. 14:503-512

Introduction Adjuvant gefitinib therapy prolonged disease-free survival in patients with resected early-stage EGFR-mutation positive NSCLC in the ADJUVANT study (CTONG 1104). However, treatment failure patterns after gefitinib therapy are less well c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee475d40bdd14a3ab708f857a8012a15
https://doi.org/10.1016/j.jtho.2018.11.020

Genomic Signatures Define Three Subtypes of EGFR-Mutant Stage II-III NSCLC With Distinct Adjuvant Therapy Outcomes

Autor: Si-Yang Liu, Ying Cheng, Fan Yang, Cheng Huang, Jian Li, Song-Tao Xu, Lin Wu, Ping Yu, Yongyu Liu, Qing Zhou, Hua Bao, Jian Su, Yang Shao, Xiao-Fei Li, Yu-Cheng Wei, Chun Chen, Xue Wu, Shi-Dong Xu, H. Ma, Ke-Neng Chen, Wei-Min Mao, Lunxu Liu, Wen-Zhao Zhong, Rong Yin, Shengxiang Ren, Hong-Hong Yan, Song Dong, Bu-Hai Wang, Shun Xu, Chen Yedan, Xu-Chao Zhang, Xue-Ning Yang, Qun Wang, Jin-Ji Yang, Zhidong Liu, Yi-Long Wu, Xiaoling Tong

The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival (DFS) of resected EGFR-mutant stage II-IIIA non-small cell lung cancer (NSCLC). However, not all patients experienced favorable c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce15d31beb93b0c80a0d959521676174
https://doi.org/10.21203/rs.3.rs-457070/v1